Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent azacytidine, achieves complete remission with or without count recovery in ∼70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy. However, the mechanism of action of this drug combination is...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Lee, Jong Bok, Khan, Dilshad H., Hurren, Rose, Xu, Mingjing, Na, Yoosu, Kang, Hyeonjeong, Mirali, Sara, Wang, Xiaoming, Gronda, Marcela, Jitkova, Yulia, MacLean, Neil, Arruda, Andrea, Alaniz, Zoe, Konopleva, Marina Y., Andreeff, Michael, Minden, Mark D., Zhang, Li, Schimmer, Aaron D.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2021
Fag:
Immunobiology and Immunotherapy
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8310428/
https://ncbi.nlm.nih.gov/pubmed/34292323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009081
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker